Best of ASCO - 2014 Annual Meeting

 

Welcome

Myeloproliferative Syndromes (MPD)

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A phase II study of cpi-0610, a bromodomain and extraterminal protein inhibitor (BETi) alone or with ruxolitinib (RUX), in patients with myelofibrosis (MF).

Marina Kremyanskaya

7056

Characteristics and outcomes of Philadelphia chromosome-negative myeloproliferative neoplasm in a tertiary institute in India: An ambispective study.

Kamal Raj Soti

e18553

Fedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): A reanalysis of the JAKARTA-2 study.

Claire N. Harrison

7057

FREEDOM: A phase 3b efficacy and safety study of fedratinib in intermediate- or high-risk myelofibrosis patients previously treated with ruxolitinib.

Srdan Verstovsek

TPS7072

Proposal of an endpoint for a phase III clinical study of essential thrombocythemia: Balancing between short term effects and long term benefits.

Ruben A. Mesa

7055

Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate or high risk relapsed/refractory myelofibrosis.

Naveen Pemmaraju

7058

Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with relapsed/refractory chronic myelomonocytic leukemia (CMML).

Mrinal Mahesh Patnaik

7059

Role of ethnicity in thrombotic and hemorrhagic complications of myeloproliferative neoplasms.

Andrew Peseski

e18555

Thrombotic episodes in myeloproliferative neoplasms: A population based study.

Somedeb Ball

e18554